Last reviewed · How we verify
Allogeneic Mesenchymal Precursor Cells — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Allogeneic Mesenchymal Precursor Cells (Allogeneic Mesenchymal Precursor Cells) — Mesoblast, Ltd.. Mesenchymal precursor cells modulate immune responses and reduce inflammation through paracrine signaling and cell-to-cell interactions.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Allogeneic Mesenchymal Precursor Cells TARGET | Allogeneic Mesenchymal Precursor Cells | Mesoblast, Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Allogeneic Mesenchymal Precursor Cells CI watch — RSS
- Allogeneic Mesenchymal Precursor Cells CI watch — Atom
- Allogeneic Mesenchymal Precursor Cells CI watch — JSON
- Allogeneic Mesenchymal Precursor Cells alone — RSS
Cite this brief
Drug Landscape (2026). Allogeneic Mesenchymal Precursor Cells — Competitive Intelligence Brief. https://druglandscape.com/ci/allogeneic-mesenchymal-precursor-cells. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing